Galectin Therapeutics Company Insiders
| GALT Stock | USD 3.50 0.01 0.28% |
Galectin Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Galectin Therapeutics suggests that vertually all insiders are extremely bullish. Galectin Therapeutics employs about 28 people. The company is managed by 23 executives with a total tenure of roughly 180 years, averaging almost 7.0 years of service per executive, having 1.22 employees per reported executive.
| Peter Traber CEO President CEO, Chief Medical Officer, Director |
| James Czirr Chairman Executive Chairman and Executive VP - Bus. Devel. |
Galectin Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-04-24 | Joel Lewis | Acquired 1000 @ 3.39 | View | ||
| 2024-04-22 | Kevin D Freeman | Acquired 2500 @ 2.98 | View | ||
| 2024-01-16 | Kary Eldred | Acquired 500 @ 1.79 | View | ||
| 2023-07-19 | Kary Eldred | Acquired 1598 @ 1.79 | View |
Monitoring Galectin Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Galectin |
Galectin Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Galectin Therapeutics' future performance. Based on our forecasts, it is anticipated that Galectin will maintain a workforce of slightly above 30 employees by June 2024.Galectin Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.9617) % which means that it has lost $0.9617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (37.2795) %, meaning that it created substantial loss on money invested by shareholders. Galectin Therapeutics' management efficiency ratios could be used to measure how well Galectin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.53 in 2024. Return On Capital Employed is likely to gain to -2.89 in 2024. At this time, Galectin Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 76.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 14.9 M in 2024.Common Stock Shares Outstanding is likely to gain to about 63.2 M in 2024, whereas Net Loss is likely to drop (36.7 M) in 2024.
Galectin Therapeutics Workforce Comparison
Galectin Therapeutics is rated # 2 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 71,929. Galectin Therapeutics adds roughly 28.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Galectin Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Galectin Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Galectin Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Galectin Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 2.0 | 4 | 2 | 6,563 | 25,000 |
| 2024-03-01 | 17.0 | 17 | 1 | 830,756 | 152,584 |
| 2023-12-01 | 7.0 | 7 | 1 | 72,895 | 100,000 |
| 2023-09-01 | 3.0 | 12 | 4 | 2,306,500 | 2,036,204 |
| 2023-03-01 | 24.0 | 24 | 1 | 825,612 | 75,529 |
| 2022-12-01 | 2.0 | 8 | 4 | 95,949 | 0.00 |
| 2022-09-01 | 1.8 | 9 | 5 | 82,443 | 30,000 |
| 2022-03-01 | 12.0 | 24 | 2 | 762,930 | 20,000 |
| 2021-12-01 | 3.25 | 13 | 4 | 1,901,449 | 40,000 |
| 2021-09-01 | 2.6667 | 8 | 3 | 1,190,839 | 30,000 |
| 2021-06-01 | 0.7273 | 8 | 11 | 2,034,353 | 85,000 |
| 2021-03-01 | 8.25 | 33 | 4 | 1,681,620 | 90,000 |
| 2020-12-01 | 6.0 | 6 | 1 | 38,894 | 10,000 |
| 2020-09-01 | 5.0 | 5 | 1 | 276,413 | 0.00 |
| 2020-03-01 | 4.25 | 17 | 4 | 832,206 | 83,513 |
| 2019-12-01 | 1.0 | 1 | 1 | 3,000 | 17,000 |
| 2019-09-01 | 1.0 | 2 | 2 | 31,290 | 38,996 |
| 2019-06-01 | 5.4 | 27 | 5 | 41,815,949 | 1,076,991 |
| 2019-03-01 | 1.75 | 28 | 16 | 4,467,849 | 3,961,218 |
| 2018-09-01 | 0.5 | 3 | 6 | 37,000 | 124,370 |
| 2018-06-01 | 0.4306 | 31 | 72 | 1,322,007 | 3,072,178 |
| 2018-03-01 | 1.25 | 5 | 4 | 309,000 | 488,888 |
| 2017-12-01 | 7.5 | 15 | 2 | 558,432 | 0.00 |
| 2017-06-01 | 1.0 | 3 | 3 | 191,410 | 1,482,315 |
| 2017-03-01 | 2.0 | 4 | 2 | 289,136 | 2,384 |
| 2016-12-01 | 3.4286 | 24 | 7 | 3,715,760 | 512,284 |
| 2016-09-01 | 2.625 | 21 | 8 | 3,339,370 | 1,515,784 |
| 2016-06-01 | 0.5 | 4 | 8 | 409,472 | 177,248 |
| 2015-06-01 | 0.8235 | 14 | 17 | 262,666 | 222,615 |
| 2015-03-01 | 7.0 | 14 | 2 | 507,019 | 259,835 |
| 2014-12-01 | 1.0 | 2 | 2 | 12,437 | 84,393 |
| 2014-09-01 | 1.75 | 7 | 4 | 36,323 | 100,000 |
| 2014-06-01 | 0.6667 | 2 | 3 | 133,334 | 130,736 |
| 2014-03-01 | 2.2353 | 38 | 17 | 1,871,789 | 769,325 |
| 2013-12-01 | 1.5333 | 23 | 15 | 1,512,348 | 1,836,000 |
| 2013-09-01 | 5.0 | 5 | 1 | 202,692 | 0.00 |
| 2013-06-01 | 2.0 | 4 | 2 | 127,176 | 146,586 |
| 2013-03-01 | 3.6667 | 11 | 3 | 154,093 | 4,298 |
| 2011-09-01 | 1.0 | 7 | 7 | 7,856,172 | 1,742,000 |
| 2011-06-01 | 1.6923 | 22 | 13 | 19,384,270 | 2,960,000 |
| 2011-03-01 | 12.0 | 12 | 1 | 6,816,957 | 370,000 |
| 2010-06-01 | 28.0 | 28 | 1 | 1,370,021 | 1,250 |
| 2009-09-01 | 15.5 | 31 | 2 | 2,205,930 | 0.00 |
| 2009-06-01 | 35.0 | 35 | 1 | 4,675,021 | 50,000 |
| 2009-03-01 | 5.0 | 20 | 4 | 5,944,503 | 268,000 |
| 2008-12-01 | 1.0 | 1 | 1 | 6,000 | 0.00 |
Galectin Therapeutics Notable Stakeholders
A Galectin Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Galectin Therapeutics often face trade-offs trying to please all of them. Galectin Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Galectin Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Traber | President CEO, Chief Medical Officer, Director | Profile | |
| James Czirr | Executive Chairman and Executive VP - Bus. Devel. | Profile | |
| Richard Uihlein | Chairman of the Board | Profile | |
| Jack CPA | Treasurer CFO | Profile | |
| Jack Callicutt | CFO | Profile | |
| Harold Shlevin | COO and Corporate Secretary | Profile | |
| Marc Rubin | Independent Director | Profile | |
| Kevin Freeman | Independent Director | Profile | |
| John Mauldin | Independent Director | Profile | |
| Arthur Greenberg | Independent Director | Profile | |
| Rex Horton | Executive Director - Regulatory Affairs and Quality Assurance | Profile | |
| Joel Lewis | Independent Director | Profile | |
| Eliezer Zomer | Executive Director of Product Devel. | Profile | |
| Stephen Shulman | Independent Director | Profile | |
| Steven Prelack | Independent Director | Profile | |
| Kary Eldred | Independent Director | Profile | |
| Gilbert Amelio | Independent Director | Profile | |
| Gilbert Omenn | Director | Profile | |
| Adam Allgood | Executive Director of Clinical Development | Profile | |
| CPA CPA | Treasurer CFO | Profile | |
| Jeff Katstra | Head Development | Profile | |
| Robert Tritt | General Counsel | Profile | |
| Beth Knowles | Executive Manager | Profile |
About Galectin Therapeutics Management Performance
The success or failure of an entity such as Galectin Therapeutics often depends on how effective the management is. Galectin Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Galectin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Galectin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.46) | (1.53) | |
| Return On Capital Employed | (3.04) | (2.89) | |
| Return On Assets | (1.46) | (1.53) | |
| Return On Equity | 0.68 | 0.65 |
The data published in Galectin Therapeutics' official financial statements usually reflect Galectin Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Galectin Therapeutics. For example, before you start analyzing numbers published by Galectin accountants, it's critical to develop an understanding of what Galectin Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Galectin Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galectin Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Galectin Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Galectin Therapeutics. Please utilize our Beneish M Score to check the likelihood of Galectin Therapeutics' management manipulating its earnings.
Galectin Therapeutics Workforce Analysis
Traditionally, organizations such as Galectin Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Galectin Therapeutics within its industry.Galectin Therapeutics Manpower Efficiency
Return on Galectin Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 429.8K | |
| Working Capital Per Executive | 523.2K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Galectin Stock analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Galectin Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galectin Therapeutics. If investors know Galectin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Return On Assets (0.96) | Return On Equity (37.28) |
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galectin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.